Myle Akshay Kiran

Dr. Myle Akshay Kiran


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2025 in Galen Medical Journal
Verified
Journal Article
Open access
PDF file
SASarah Mohammed Almuhanna
Sarah Mohammed Almuhanna
OAOmar Ahmed Alshehri
Omar Ahmed Alshehri
BABandar Mohammed B Alsaadooni
Bandar Mohammed B Alsaadooni
MAMohammed Hassan Mohammed Alawad
Mohammed Hassan Mohammed Alawad
AAAbdullah Mohammed Alnasyan
Abdullah Mohammed Alnasyan
MKMyle Akshay Kiran
Myle Akshay Kiran
Background: There are many children worldwide who suffer from ECDD and these delays may negatively affect their health, education and integration with others in long-term. Identifying developmental delays at an early stage is sometimes difficult due to the absence of standardized methods, misconceptions and little training in healthcare. Developmental delays must be handled carefully so that they do not cause harm children in the long run. Materials and Methods: The systematic review included 16 articles according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The review included research only on developmental delays happening in the domains of cognitive, language, motor or social-emotional skills. Results: The review looks at the latest findings on the diagnosis, treatment and results connected to ECDD. A pooled meta-analysis of seven studies indicated that children from low-income households had a significantly higher risk of developmental delays, with a combined odds ratio (OR) of 2.38 (95% Confidence Interval [CI]: 1.75–3.22, p < 0.001). Protective factors were also identified; for example, three studies showed that access to early childhood education programs reduced the risk of ECDD, with an OR of 0.61 (95% CI: 0.43–0.86). Conclusion: The study highlights the importance of having policies that focus on early detection and complete care to support children’s healthy development and good quality of life. The review notes that future research should also make it a priority to study how early intervention affects long-term outcome in various kinds of contexts and population.

20 January 2025 in Galen Medical Journal
Verified
Journal Article
Open access
SSSafa Saeed
Safa Saeed
JAJawaher Alhababi
Jawaher Alhababi
FAFatimah Alanazi
Fatimah Alanazi
AAAmal Albarrak
Amal Albarrak
HAHalh Alabdulmonem
Halh Alabdulmonem
MKMyle Akshay Kiran
Myle Akshay Kiran
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare genetic disorder caused by a point mutation in the LMNA gene that encodes lamin A. This mutation results in the production of progerin, a defective protein that accelerates cellular aging. This review explores the oral and dental manifestations of HGPS, emphasizing their role in early diagnosis, management strategies, and the potential for targeted therapies. A thorough review of existing literature was conducted to summarize the phenotypic characteristics, oral health implications, and current approaches for the management of HGPS-related complications. Individuals with HGPS exhibit age-associated complications starting in early childhood, including distinct craniofacial abnormalities and severe oral health challenges. Common oral manifestations include delayed tooth eruption, microdontia, malocclusion, dental caries, tooth loss, and mandibular osteolysis. These abnormalities necessitate a multidisciplinary approach involving pediatric dentists, orthodontists, oral surgeons, and geneticists to deliver comprehensive care. Understanding the pathophysiological mechanisms behind HGPS oral anomalies is vital for improving diagnosis and treatment. Advances in genetic research hold promise for developing targeted interventions to alleviate dental complications and enhance the quality of life for affected individuals. Ongoing research and a collaborative care approach are essential to address the challenges posed by HGPS effectively.

31 July 2023
Verified
Journal Article
Open access
PDF file
MKMyle Akshay Kiran
Myle Akshay Kiran
MBMuhammed Bakhrebah
Muhammed Bakhrebah
MHMUHAMMAD HALWANI
MUHAMMAD HALWANI
BAbashayer alshahil
bashayer alshahil
AOAbdulrazzag Abdulaziz Othman
Abdulrazzag Abdulaziz Othman
ARAli A. Rabaan
Ali A. Rabaan
Introduction: The COVID-19 pandemic caused by the SARS-CoV-2 virus has affected millions worldwide. In this study, we investigate the potential of CRISPR systems Cas12 and Cas13 for diagnosing and treating RNA viruses, particularly SARS-CoV-2. Aim: This study aims to explore the role and application of CRISPR-system-based methods in detecting and treating RNA viruses, especially SARS-CoV-2, using Cas12 and Cas13 proteins. Materials and Methodology: CRISPR enzymes, types V and VI, can target RNA or DNA through processes known as RNA and DNA targeting. Cas12 and Cas13 enzymes are specific for single-stranded RNA viruses and play a crucial role in diagnosing and treating these viruses. We used the DETECTR assay to detect mutations in SARS-CoV-2, including circulating and rare or new variants, in 304 respiratory swab samples collected from patients.